Business
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
FEATURED STORIES
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.
The U.S. FDA has approved Lynparza for the adjuvant treatment of patients diagnosed with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Bristol Myers Squibb and Nektar Therapeutics said their joint Phase III PIVOT IO-001 study did not meet two endpoints: progression-free survival and objective response rate.
Harpoon Therapeutics, Inc. has unfortunately announced that it will move to discontinue one of its promising T cell engager biologics, HPN424.
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
The two companies will work closely to harness the abilities of dopamine receptor modulators to help patients living with complex neuropsychiatric conditions.
More than two dozen people were given the opportunity to confront members of the Sackler family in a virtual environment and share the impactful pain opioid addiction caused their families.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers